Oncology News | pharmaphorum

News

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers wit

News

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i

News

BMS’ LAG-3 RELATIVITY theory fails futility test

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)

Eisai files biliary tract cancer drug tasurgratinib in Japan

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

BMS’ LAG-3 RELATIVITY theory fails futility test

MSD claims 2nd FDA approval for Welireg, in kidney cancer

MSD, Moderna cancer vaccine aces melanoma study

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks